Grant received in 2021
DCCC has funded 158.838 DKK to the project
According to Danish and international guidelines the best treatment option in first-line for patients with inoperable pancreatic cancer is combination chemotherapy, whereas old and/or fragile patients could be offered Gemcitabine monotherapy. Randomized phase 3 trials show improved effect of combination chemotherapy compared to Gemcitabine, but these trials are restricted to patients younger than 75 years and in good general condition as the toxicity of combinations is increased. As studies in metastatic colorectal cancer suggest that reduced dose of combination chemotherapy may be better than monotherapy for elderly and frail patients, we hypothesize that a reduced dose of combination chemotherapy may improve results in elderly or frail patients with pancreatic cancer as well. The primary endpoints of this DPCG-initiated study will be overall survival and patient-reported outcome.
Multidisciplinary organisation
Danish Pancreas Cancer Gruppe (DPGC)
Project stakeholders
- Louise Skau Rasmussen, Registrar, PhD, Department of Oncology, Aalborg University Hospital. Primary contact, Mail: loskr@rn.dk
- Morten Ladekarl, Consultant, DMSc., Professor, Department of Oncology, Aalborg University Hospital
- Per Pfeiffer, Consultant, Professor, Department of Oncology, Odense University Hospital
- Inna Chen, Specialty Registrar, Department of Oncology, Herlev University Hospital
- Britta Weber, Consultant, PhD, epartment of Oncology, Aarhus University Hospital
- All are oncologists and members of DPCG's steering committee